|
KMID : 1100720180380060538
|
|
Annals of Laboratory Medicine
2018 Volume.38 No. 6 p.538 ~ p.544
|
|
|
Serum Copeptin Levels Predict Clinical Outcomes After Successful Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
|
|
Choi Hyun-Jung
Kim Min-Chul
Sim Doo-Sun
Hong Young-Joon
Kim Ju-Han
Jeong Myung-Ho
Kim Soo-Hyun
Shin Myung-Geun
Ahn Young-Keun
|
|
|
Abstract
|
|
|
Background: Serum copeptin has been demonstrated to be useful in early risk stratification and prognostication of patients with acute myocardial infarction (AMI). However, the prognostic value of copeptin after percutaneous coronary intervention (PCI) for clinical outcomes remains uncertain. We investigated the prognostic role of serum copeptin levels immediately after successful PCI as a prognostic marker for major adverse cardiac events (MACE; comprising death, repeat PCI, recurrent MI, or coronary artery bypass grafting) in patients with AMI.
Methods: A retrospective study was performed in 149 patients with AMI who successfully received PCI. Serum copeptin levels were analyzed in blood samples collected immediately after PCI. The association between copeptin levels and MACE during the follow-up period was evaluated.
Results: MACE occurred in 34 (22.8%) patients during a median follow-up of 30.1 months. MACE patients had higher copeptin levels than non-MACE patients did. Multiple logistic regression analysis showed that the increase in serum copeptin levels was associated with increased MACE incidence (odds ratio=1.6, P=0.005).
Conclusions: A high level of serum copeptin measured immediately after PCI was associated with MACE in patients with AMI during long-term follow-up. Serum copeptin levels can serve as a prognostic marker in patients with AMI after successful PCI.
|
|
|
KEYWORD
|
|
|
Copeptin, Prognosis, Major adverse cardiac events, Myocardial infarction, Percutaneous coronary intervention
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|